Uncategorized
Patent granted for method of use of Acucela’s Stargardt disease treatment
The U.S. Patent and Trademark Office granted U.S. Patent No. 9,737,496 B2 to Acucela for method of use of its Stargardt disease treatment emixustat hydrochloride or a “broad number of related compounds,” according to a company press release.Emixustat was granted orphan drug designation in January for the treatment of Stargardt disease, which affects fewer than 40,000 patients in the United States.